Your binder contains too many pages, the maximum is 40.
We are unable to add this page to your binder, please try again later.
This page has been added to your binder.
NEW YORK, NY, December 2, 2008 — Roche and Memory Pharmaceuticals have announced a definitive merger agreement for Roche to acquire all the outstanding shares of Memory Pharmaceuticals. Covington & Burling LLP advised Memory Pharmaceuticals on the deal, valued at approximately $50 million.
Roche, headquartered in Switzerland, is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. Memory Pharmaceuticals develops innovative drug candidates for the treatment of debilitating central nervous system (CNS) disorders such as Alzheimer’s disease and schizophrenia.
The Covington corporate team was led by New York-based partners Ellen Corenswet and J. D. Weinberg, and associates Andrew Hyman, Michelle Garcia and Edward Tsai*, and Washington-based associate Keir Gumbs. The Covington team also included partner Corinne Goldstein (environmental), partner Robert Newman (employee benefits), partners Nigel Howard and Amy Toro (intellectual property and collaborations), partner Grail Sipes (FDA) and associate David Fagan (CFIUS).
*Not yet admitted to practice.